AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01739816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication review
Description: Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer.
Study NCT01739816 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medication review
Description: Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer.
Study NCT00944073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Description: Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 micrograms per dose. Both doses of the vaccine will be administered as a single 0.5 mL injection in the deltoid muscle of the preferred arm or into the anterolateral thigh muscle.
Study NCT02001298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Study NCT02001298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroprusside
Study NCT03629379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
Study NCT03629379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
Study NCT04587752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Weight Bullying
Description: Cognitive-behavioral therapy for weight-related bullying delivered by audio/video telehealth.
Study NCT05271370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 350
Description: Pro140 SC injection 350 mg
Study NCT05271370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 525
Description: 525 mg
Study NCT05271370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 700
Description: 700 mg
Study NCT03699553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain
Description: 8 positive emotion skills taught over 5-6 weeks to help individuals cope with chronic pain and stress.
Study NCT03699553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion Reporting Control Group
Description: Attention matched control condition, participants will report their daily emotions over 5-6 weeks online.
Study NCT04538001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon implantation
Description: Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and balloon implantation.
Study NCT04538001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and partial repair
Study NCT02234648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 60mL tart Montmorency cherry juice
Description: One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
Study NCT02234648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
Study NCT04490382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 32 channel external stimulator
Description: Patients will be stimulated by the 32 channel external stimulator via leads placed as part of standard care neuromodulation. Then patients will undergo various tasks.
Study NCT03535597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quikclot Radial (QC) Pad
Description: The QC pad will be applied over the radial artery access site covered with either a Coban™ bandage, a Tegaderm™ dressing, or a TR Band after TRA.
Study NCT03942185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy
Description: Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Study NCT03942185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Chinese Herbal Medicine according with syndrome differentiation therapy
Description: Oral Chinese Herbal Medicine according with syndrome differentiation therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Study NCT03942185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy
Description: Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Study NCT01476098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SB-705498 placebo
Study NCT01476098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: SB-705498 placebo
Study NCT01476098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB-705498
Description: 400 or 600mg oral SB-705498
Study NCT01476098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB-705498
Description: 400 or 600mg oral SB-705498
Study NCT02183844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Weight Intervention
Description: Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
Study NCT04660591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femoral stem in hip arthroplasty
Description: using lateral approach to the hip we will compare the effect of femoral stem length on the oncological and functional outcomes in patients with proximal femoral metastasis.hip arthroplasty is a surgical procedure that involves changing the head of the femur (the ball) with or without replacing the articular surface of the acetabulum (the socket ).and replacing it with metal head based on a stem covered with cement to fix it to the bone of the femur.
Study NCT03180177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The second HIPEC regimens are cisplatin 75 mg/m\^2, 43°C, 90min.
Study NCT03180177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interval debulking surgery
Description: Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.
Study NCT03180177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interval debulking surgery
Description: Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.
Study NCT03180177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group.
Study NCT03180177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group.
Study NCT03180177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group.
Study NCT03180177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group.
Study NCT03510494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented physical education program
Description: Augmented physical education program
Study NCT00555594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Avastin)
Description: One dose of 0.1cc of subconjunctival Bevacizumab was applied
Study NCT01344954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Administered intravenously over 10 minutes
Study NCT01344954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Administered orally as a capsule once a day for 35 days
Study NCT00816478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galactose
Description: Oral galactose, 0.2 g/kg/dose twice daily for 28 days
Study NCT03316820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after an overnight fast
Study NCT03316820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after food
Study NCT04589871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping technique
Description: Fixmull stretch and Leukotape (rigid tape) were used in taping to guide the patellar trajectory orientation while performing the movement. Individuals were asked to lay down in supine position with knee in a slightly bent position. Fixomull stretch was used as an adhesive pre-wrap to protect the skin and provide some of the checking force. The main check strap was provided by stripes of rigid tape (Leukotape). The knee cap was taped, started on the outer aspect of the knee cap and pulled inwards. Finished at the back of the inside of the knee. Two further pieces of tape (Fixomull Stretch and Leukotape) applied distal to the patella unloaded the infrapatellar fat pad.
Study NCT04589871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A supervised exercise protocol
Description: Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
Study NCT01254240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA / UVB phototherapy
Description: UVA / UVB phototherapy
Study NCT01254240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVB phototherapy
Description: UVB phototherapy
Study NCT04589871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A supervised exercise protocol
Description: Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
Study NCT00754585 — intervention group
Intervention type: DEVICE
Intervention: Logic Back Grahl Duo Back Model DB11-01
Description: The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
Study NCT00142181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
Study NCT02592993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay device
Description: The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
Study NCT00950794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol(SN408D)
Description: Salmeterol(SN408D)：long-acting Beta2-agonist
Study NCT00950794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hokunalin (tulobuterol) tape
Description: Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
Study NCT02138084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study NCT02138084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin
Study NCT02138084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir
Study NCT01296789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue perfusion guided protocol
Description: A tissue perfusion guided protocol is used to guide hemodynamic therapy
Study NCT01296789 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care
Study NCT03254446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC150094
Description: TRC150094 Tablet 45 mg
Study NCT03254446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Tablet
Study NCT00381615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB
Description: One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
Study NCT00381615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV
Description: One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
Study NCT00381615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-Hib-IPV
Description: Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
Study NCT00381615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PC7
Description: IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
Study NCT00381615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-CRM
Description: MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
Study NCT00381615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-Hib
Description: MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
Study NCT00381615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
Study NCT01654926 — intervention group
Intervention type: PROCEDURE
Intervention: blood ultrafiltration
Study NCT01135134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: The study drug is MFNS (50 μg spray device) and the dose will be:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks
Study NCT01135134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MF Placebo nasal spray and administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks
Study NCT04073121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminor DCB and Angiolite DES
Description: Patient to undergo angioplasty with Luminor DCB and Angiolite DES
Study NCT01059409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscal Allograft
Description: Meniscal Allograft
Study NCT01546558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg bid on Days 1-10
Study NCT01546558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine 500 mg bid on Days 6-10
Study NCT03898726 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopical l cuff closure
Description: closure of vaginal cuff following hysterectomy
Study NCT01496235 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dark chocolate
Description: Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
Study NCT01496235 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White chocolate
Description: Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
Study NCT02595073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS
Description: Active treatment
Study NCT02595073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study NCT00134303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is used.
Study NCT00631358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxidex
Description: Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
Study NCT02046889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bicycle Training Intervention
Study NCT00151580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 18 months of oral ribavirin maintenance treatment
Study NCT00631358 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No treatment
Description: Healthy normal control group receiving no treatment
Study NCT00151580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 18 months oral placebo treatment
Study NCT02512640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volume-controlled ventilation
Description: a tidal volume of 8 ml/kg
Study NCT02512640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure-controlled ventilation
Description: a peak airway pressure to maintain a tidal volume of 8 ml/kg
Study NCT02647775 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: multi-port VATS
Description: Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
Study NCT02647775 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: single-port VATS
Description: Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
Study NCT00568412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zarzenda
Description: Topical cream, applied twice daily for three weeks
Study NCT00568412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel
Description: 1% cream, applied topically twice daily for three weeks
Study NCT01737827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: INC280 was administered orally on a continuous twice a day (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle. INC280 was initially supplied as hard gelatin capsules and subsequently also as film-coated tablets.